Attenuation of Fos-like immunoreactivity in the trigeminal nucleus caudalis following trigeminovascular activation in the anaesthetised guinea-pig

Brain Research
J S ClaytonD T Beattie

Abstract

The present study has examined the involvement of sensory neurotransmitters in activating neurones in the trigeminal nucleus caudalis following stimulation of the trigeminovascular system in anaesthetised guinea-pigs. Electrical stimulation of the right trigeminal ganglion produced a unilateral expression of Fos-like immunoreactivity (Fos-LI) in the trigeminal nucleus caudalis. The tachykinin NK1 receptor antagonist, GR205171 (100 micrograms/kg i.v.) and the N-methyl-D-aspartate (NMDA) receptor antagonist, MK-801 (1 mg/kg i.v.) each inhibited expression of Fos-LI following electrical stimulation. The calcitonin gene-related peptide (CGRP) receptor antagonist, CGRP8-37 (1.3 mg/kg i.v.), administered following rostral intracarotid infusion of mannitol to disrupt the blood-brain barrier, tended to reduce Fos-LI evoked by electrical stimulation, although this failed to reach statistical significance. Capsaicin (10 nmol in 0.1 ml), administered intracisternally, produced a bilateral expression of Fos-LI in the trigeminal nucleus caudalis. This expression was unaffected by the peripherally acting NK1 receptor antagonist, GR82334 (0.2 mg/kg i.v.) or CGRP8-37 (1.3 mg/kg i.v.). The centrally penetrant NK1 receptor antagonist, GR205171 (...Continue Reading

Citations

May 24, 2001·Current Opinion in Neurology·A May, P J Goadsby
Aug 29, 2000·Cephalalgia : an International Journal of Headache·R H KemperG J Ter Horst
Apr 3, 2001·Expert Opinion on Investigational Drugs·A May, P J Goadsby
Sep 29, 2006·The European Journal of Neuroscience·A BergerotP J Goadsby
Mar 13, 2014·British Journal of Pharmacology·S E Erdener, T Dalkara
Oct 25, 2003·American Journal of Pharmacogenomics : Genomics-related Research in Drug Development and Clinical Practice·Kelly L RogersLyn R Griffiths
May 12, 2006·Cephalalgia : an International Journal of Headache·U ArulmaniP R Saxena
Aug 22, 2013·Expert Opinion on Drug Discovery·Sieneke LabruijereAntoinette Maassenvandenbrink
Jun 3, 2011·Headache·Saurabh GuptaB Lee Peterlin
Dec 5, 2002·Current Medical Research and Opinion·N M Ramadan
May 3, 2008·Current Opinion in Neurology·Katharina Eikermann-Haerter, Michael A Moskowitz
Feb 13, 1999·Progress in Neurobiology·M J Millan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.